Pharmaceutical - Johnson & Johnson, Dermatologicals

Filter

Popular Filters

Janssen’s guselkumab shows significant efficacy in moderate to severe plaque psoriasis

25-03-2014

New findings presented for the first time at the 2014 Annual Meeting of the American Academy of Dermatology…

DermatologicalsguselkumabHumiraJanssenJohnson & JohnsonPharmaceuticalResearch

Four medicines recommended for approval by EMA/CHMP

Four medicines recommended for approval by EMA/CHMP

22-12-2013

Following regular monthly meeting of the European Medicines Agency’s Committee for Medicinal Products…

AlconAntibiotics and Infectious diseasesComtriqDermatologicalsEuropeGaldermaJanssen-CilagJohnson & JohnsonMirvasoNovartisOncologyOphthalmicsPharmaceuticalRegulationSirturoTMC Pharma Services

Sales of psoriasis drugs to be worth $7.4 billion by 2020

19-04-2013

The psoriasis market experienced approximately 36.5 million prevalent cases across the USA, France, Germany,…

AbbVieAmgenAsia-PacificDermatologicalsEnbrelEuropeHumiraJohnson & JohnsonMarkets & MarketingNorth AmericaNovartisPfizerPharmaceuticalsecukinumabStelara Injectiontofacitinib

Janssen files NDA with FDA for canagliflozin in type 2 diabetes

01-06-2012

Janssen Research & Development, a subsidiary of health care giant Johnson & Johnson (NYSE: JNJ) has submitted…

canagliflozinDermatologicalsJanssenJohnson & JohnsonMitsubishi TanabeNorth AmericaPharmaceuticalRegulation

Back to top